Gland Pharma Hits 4-Year High After Strong Q2 Show

GLAND Shares of Gland Pharma surged nearly 8% to hit a four-year high of Rs 3,372 on the NSE on Monday, following robust second-quarter results for FY27. The stock settled 4.86% higher at Rs 3,***** Hyderabad-based pharma major reported a 58.3% year-on-year jump in consolidated net profit to Rs 290.75 crore, while revenue from operations rose 23% to Rs 1,833.58 crore. Growth was driven by strong execution across businesses, higher sales in key European and US markets, and a 31% rise in its contract development and manufacturing organisation (CDMO) ***** company launched four molecules in the US during the quarter and continues to expand its product pipeline. Executive Chairman Srinivas Sadu highlighted solid performance and said the firm remains well-positioned to capitalise on global outsourcing opportunities through ongoing investments in capacity and innovation.